Shawn Marcell Headshot April 2017.jpg

SHAWN MARCELL

ReadCoor | Chairman, CEO and Co-Founder

Shawn Marcell has 25 years of executive experience leading interdisciplinary teams in technology and the life sciences. His background includes venture creation, growth acceleration and raising more than $300M in capital for private and public companies.

Prior to co-founding ReadCoor, Shawn was an Executive in Residence at Harvard University’s Wyss Institute for Biologically Inspired Engineering. At the Wyss, he oversaw a talented team of business professionals in the development of the ReadCoor business plan and corporate strategy. The team went on to raise one of the largest series A financings in 2016 and was featured in the journal Nature Biotechnology as top ten startup of the year. Shawn has founded and chaired several early stage venture-backed companies in the life sciences including RedPoint Bio (public in 2005), SeniGen (acquired by Sequenom), Lifecodes (division of Hologic acquired by Immucor), and Metamark Genetics.

In addition to launching multiple startups, Shawn’s leadership experience includes large corporations, academic institutions and venture capital funds. He taught entrepreneurship and venture creation at University of Pennsylvania’s Wharton School, and was President of the Port of Technology in Philadelphia, one of the largest life sciences and technology incubators in the United States. He launched and led the University City Science Center’s inaugural venture fund in Philadelphia, and served as Executive in Residence at Excel Venture Management, a leading Boston life sciences technology venture fund. Currently Shawn is a member of the Monell Chemical Senses Center’s International Advisory Council, and a Fellow and Advisory Board Member of the University of Pennsylvania’s Weiss Tech House.

For more than two decades, Shawn has been actively engaged in philanthropic causes. He was a Founder and Board Member of Gilda’s Club in New York City, a community provider of support services for cancer patients and their families. He served as Chairman of the Board of The Calcutta House in Philadelphia, an organization providing residential care facilities for people living with AIDS. Most recently he established a martial arts program at Nashoba Learning Group in Bedford, Massachusetts for children and adults with autism spectrum disorder. He holds a Bachelor of Arts in Economics from George Washington University.


Grogan 2.jpg

Thomas M. Grogan, MD

Ventana Medical Systems, Inc., a member of the Roche Group | Founder Emeritus
University of Arizona | Professor Emeritus of Pathology,

Thomas M. Grogan is an accomplished life sciences leader with more than four decades of experience as a clinical pathologist and executive manager. He is the Founder (Emeritus) of Ventana Medical Systems, Inc., a world leader and innovator of tissue-based diagnostic solutions for patients worldwide, and Professor Emeritus of Pathology at the University of Arizona College of Medicine. He also serves as a mentor and scientific advisor to Ventana and Roche Tissue Diagnostics’ team of researchers.

Grogan began his career in pathology shortly after receiving his Bachelor of Arts in Biology from the University of Virginia. Following his graduation, he worked alongside Dr. Chapman Binford, a renowned scientist at the Armed Forces Institute of Pathology, on a leprosy research study funded by the National Institutes of Health.  Under Binford’s tutelage, Grogan was introduced to pathology and inspired to pursue a Doctor of Medicine from George Washington University. Upon receiving his medical degree in 1971, Grogan became a pathology resident at Letterman Army Medical Center, followed by Chief of the Hematology lab at Walter Reed Army Medical Center. He later went on to complete a post-doctoral fellowship in hematopathology at Stanford University at the recommendation of Dr. Costan Berard, a key figure in American hematopathology.

Grogan joined the faculty at the University of Arizona in 1979, and since then has been actively involved in teaching residents, medical students and fellows. A few years later in 1985, Grogan and a small team of highly skilled doctors, scientists, and engineers formed Ventana Medical Systems. Grogan and his colleagues pioneered automated and standardized tissue biopsy testing to deliver diagnostic results to patients more swiftly and with greater accuracy and reliability. Since being acquired by Roche in 2008,  Ventana has grown to be the world’s leading developer and manufacturer of tissue-based diagnostic instruments and tests focused on the detection and treatment of cancer.

Grogan is also a founding member of the International Lymphoma Study Group, a group of scientific leaders responsible for formulating the current World Health Organization classification scheme for clinical practice.  He has authored more than 250 papers on lymphoma and myeloma, and holds patents for the kinetic-mode process for automated immunohistochemistry (IHC) and in-situ hybridization (ISH).


Richard Terry Headshot April 2017.jpg

Richard Terry

ReadCoor | Founder, President, and CTO

For more than 15 years, Richard Terry has led cross-functional teams in the development of innovative and novel technologies. His unique background in aerospace engineering, physics and biochemistry is a testament to his ability to transcend barriers and bring together a diverse set of resources to achieve the impossible. Richard’s research interests include applying systems-level engineering to biological challenges, and he is a prominent expert in synthetic biology. 

Prior to launching ReadCoor, Richard was Lead Senior Staff Scientist at Harvard University’s Wyss Institute for Biologically Inspired Engineering. At the Wyss, he supported advancements in reading, writing and editing nucleic acid, better known as nucleic acid sequencing, gene synthesis, and gene editing. Richard was one of the institute’s first hires and joined the founding team before the research center opened its doors. He built and transformed the Synthetic Biology group from its earliest form into the world-renowned Translational Synthetic Biology group that it is today.  A sample of the tools developed by the Synthetic Biology group under his charge includes Ultra-Long DNAs, Next Gen Sequencing, Nanopore Sequencing, Multiplexed Automated Genome Engineering (MAGE), Programmable DNA Nanotherapeutic Robotic Device, CRISPR, TALEN, Zinc Finger, CADnano, SeqTag, Data Encoding and Enzymatic Synthesis of DNA.

Before joining the Wyss, Richard resided in the Church Lab at Harvard Medical School. During his time in the lab he designed, developed, and produced a cost-effective, high throughput, open source DNA sequencer: The Polonator. Prior to his time at the Church Lab, Richard developed implantable nerve stimulation devices to treat vestibular disorders at the Massachusetts Eye and Ear Infirmary. He also held the position of Senior Project Manager for an optical subsystem of the Large Hadron Colliders (LHC) at The Center of European Nuclear Research (CERN) in Geneva, Switzerland. While completing his graduate degree and following its completion, he conducted urology research for diagnostic devices at Boston Medical Center.  He has served as a consultant for a diverse selection of companies ranging from medical device startups to large manufacturing firms (Johnson & Johnson, NeuroKinetics, Intelligent Bio Systems, Good Start Genetics, ABVitro, Merck, Fero Solutions, Halcyon Molecular, Gen9, and Helicos Biosciences). Additionally, he founded a DNA sequencing chemistry company and an engineering consulting firm. Terry received his Master of Science in Aerospace Engineering from Boston University, and has numerous patents and publications spanning multiple disciplines.


victorportrait_2.jpg

Victor E. Tong

Decheng Capital | Partner

Mr. Victor E. Tong, Jr. is a Partner at Decheng Capital and has been with the firm since its inception. At Decheng, Mr. Tong focuses on investments in biotechnology and medical technology companies in China and US. Mr. Tong currently serves on the boards of Accuragen, EpimAb Biotherapeutics, GenapSys, GeneMDx, Levitas, ReadCoor and SentreHeart. He previously served on the boards of past Decheng companies Cirina (acquired by GRAIL) and GeneWEAVE Biosciences (acquired by Roche). Mr. Tong’s investment portfolio also includes 3SBio (1530.HK), Apexigen, ARMO Biosciences, Cellular Research (acquired by Becton Dickinson), China Biologic Products (NASDAQ: CBPO), Hummingbird Bioscience, Invitae (NASDAQ: NVTA) and SINOMED.
 
Prior to joining Decheng, Mr. Tong was a Principal at Bay City Capital and was a member of the founding team of Nevro (NYSE: NVRO), a Bay City Capital-originated medical device company. He also played a key role in the firm’s investments in Cadence Pharmaceuticals (acquired by Mallinckrodt), GenturaDx (acquired by Luminex), Ion Torrent Systems (acquired by Life Technologies) and NextWave Pharmaceuticals (acquired by Pfizer). Prior to joining Bay City, Mr. Tong was an investment banker with Morgan Stanley, where he advised healthcare companies on initial public offerings and specialized in strategic advisory work. Prior to Morgan Stanley, Mr. Tong was an entrepreneur at Hana Biosciences (acquired by Spectrum Pharmaceuticals), where he was responsible for pipeline development, licensing and product launch for cancer products. Mr. Tong began his career participating in The Human Genome Project and its race to sequence the human genome as a research assistant at Incyte in 1999.
 
Mr. Tong is a graduate of the University of California, Berkeley, where he earned a BA degree in Molecular and Cell Biology and a BS degree in Business Administration from the Haas School of Business.


Tsay 2016.jpg

Yuh-geng TSAY, PhD

Vivo Capital | Venture Partner

Dr. Tsay joined Vivo Capital in 2016 as a Venture Partner. He has extensive experience and track record in building successful businesses that were eventually acquired or went public. Prior to his retirement in 2010 from Thermo Fisher Scientific (NYSE: TMO), Dr. Tsay served as Senior Vice President and Group President of the company’s Specialty Diagnostic business, with worldwide annual revenue of US $2 billion. He was the Group President of Immunodiagnostics of Fisher Scientific (NYSE: FSH) prior to Fisher’s merger with Thermo Electron in 2006. From 2000 to 2004 he served as Group President of Clinical Diagnostics of Apogent (NYSE: AOT), which was acquired by Fisher in 2004. While working for these public companies, he was instrumental in engineering the acquisition of multiple diagnostics companies including Phadia, One Lambda, BRAHMS, Microgenics, Seradyne, Duke Scientifics and Applied Biotech Inc. He was the founder of Diagnostics Reagents Inc., which was acquired by Apogent in 1998. He also cofounded several other diagnostic companies, which were either acquired by a public company or went public.

Dr. Tsay serves on the boards of several biotech companies including PEG Bioscience, PharmaLegacy, AltheaDx, ReadCoor and Bonraybio. He also serves as a Scientific Advisor for Personal Genomics.

Dr. Tsay received his B.S. in Chemistry from the National Cheng Kung University in Taiwan. He has a Ph.D. degree in Organic Chemistry from the University of Rochester, New York. He received a Distinguished Scholar Award from the University of Rochester (2014) and the Distinguished Alumni Awards from Cheng Kung University (2012).